• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

UPDATE: BTG’s U.S. Biocompatibles business to pay $36m settlement, plead guilty to misbranding

November 8, 2016 By Brad Perriello

BTG

Updated to include BTG’s guilty plea entered Nov 7.

BTG (LON:BTG) said today that it agreed to pay the U.S. Justice Dept. $36 million (£28.4 million) to settle a probe into the marketing of the LC Bead embolization microspheres made by its Biocompatibles subsidiary.

The company plead guilty on Monday, November 7, to charges of improperly marketing its embolic LC Bead device.

Biocompatibles admitted to a misdemeanor charge of introducing a misbranded medical device into interstate commerce, according to court documents.

The company is slated to pay $8.75 million criminal fine and $2.25 million in criminal forfeiture onto of $25 million for civil claims under the federal False Claims Act.

In signed court papers, the company admitted to having market its LC Bead as a drug delivery device between 2006 and 2010, despite having told the FDA earlier that it would not market it as such.

The Justice Dept. launched the probe in July 2014, saying it would investigate the marketing practices for LC Bead from 2003 to 2011, covering a period before the January 2011 buyout of Biocompatibles by the British drug-delivery giant. The settlement does not include a corporate integrity agreement, BTG said.

“It is good to resolve this legacy issue. We understand our responsibilities to patients and healthcare providers and, in addition to our robust ethics and compliance program, we strive to have a corporate culture where we do the right thing, every time. This allows us to focus on what we do best: delivering innovative therapies to improve people’s lives,” CEO Louise Makin said in prepared remarks.

In a separate release, BTG said its preliminary half-year results are expected to top its revenue guidance of $645.6 million to $683.5 million (£510 million to £540 million) for the 6 months ended Sept. 30.

“Strong growth in interventional medicine revenues reflects continued good performances from interventional oncology, which included the 1st revenues from Galil Medical following its acquisition in June 2016, and from EKOS. Varithena revenue reflects the gradual increase in customers and reorder rates during the period, while PneumRx revenues are lower than last year, reflecting the current interim reimbursement environment in Germany,” BTG said in a press release. “Specialty pharmaceuticals has delivered a good performance across the portfolio. In licensing there were good performances from Zytiga and Lemtrada, while year-on-year growth was held back by the 1-off uplift of £8.5m ($10.8 million) in the prior period for Zytiga.”

“We have had a strong 1st half, delivering double-digit constant currency revenue growth as we have continued to grow the business. The acquisition of Galil Medical has strengthened and diversified our interventional oncology portfolio, which also saw the U.S. launch of our innovative visible bead LC Bead Lumi and approval in Canada of DC Bead Lumi. We anticipate further progress in the 2nd half of the year, including the E.U. approval of DC Bead Lumi, completing the U.S. [pre-market approval] submission for the PneumRx coil and the launch in Canada of Varithena,” Makin said.

BTG said it plans to release its full 1st-half results Nov. 15.

Material from Reuters was used in this report.

Filed Under: Drug-Device Combinations, Legal News, Wall Street Beat Tagged With: BTG, U.S. Justice Dept.

IN CASE YOU MISSED IT

  • Flat Medical partners with Mercury Medical on smart syringe distribution
  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS